Novartis AG (NOVNEE.SW)

Switzerland · Industrial & Consumer Products · CHF

Key financials

ROE: 31.01%; 2025 (actual)
ROA: 13.12%; 2025 (actual)
Gross Margin: 75.83%; 2025 (actual)
Net Margin: 24.67%; 2025 (actual)
Total Assets: CHF 110,949.00M; 2025 (actual)
Net Income: CHF 13,984.00M; 2025 (actual)
Valuation: CHF 2,772,447.57M; 2026 (forecast)
Stock Price: -

Historical & projected performance

Reported figures and Equlion model projections for the next 5 years.

Metric	2025 (actual)	2026 (forecast)	2027	2028	2029	2030	2031
ROE	31.01%	29.21%	26.63%	26.88%	25.47%	22.74%	19.22%
Sector average	-	16.79%	13.29%	12.34%	10.49%	-0.78%	4.08%
ROA	13.12%	10.99%	9.93%	11.38%	11.8%	11.46%	10.49%
Sector average	-	5.08%	5.34%	5.48%	5.24%	4.72%	3.7%

Amounts in CHF (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.

Want the full financial forecast report for Novartis AG? It covers the balance sheet, income statement and Equlion model projections.

Net Margin	24.67%	22.5%	22.16%	22.73%	23.02%	23.22%	23.27%
Sector average	-	6.07%	6.13%	6.18%	6.19%	6.21%	5.54%

Total Assets	CHF 110,949.00M	CHF 122,033.00M	CHF 135,180.25M	CHF 161,225.05M	CHF 190,859.81M	CHF 220,709.49M	CHF 247,502.73M
Sector average	-	CHF 7,768.94M	CHF 8,725.65M	CHF 10,122.27M	CHF 11,543.79M	CHF 12,787.42M	CHF 33,292.03M

Net Income	CHF 13,984.00M	CHF 12,806.12M	CHF 12,764.61M	CHF 16,864.28M	CHF 20,769.19M	CHF 23,584.49M	CHF 24,569.07M
Sector average	-	CHF 546.58M	CHF 622.88M	CHF 786.44M	CHF 922.54M	CHF 998.31M	CHF 2,915.68M

Valuation	-	CHF 2,772,447.57M	CHF 2,829,210.54M	CHF 2,883,240.66M	CHF 2,934,809.26M	CHF 2,985,201.44M	CHF 3,036,542.14M
Sector average	-	CHF 50,018.16M	CHF 51,017.60M	CHF 51,973.86M	CHF 52,895.09M	CHF 53,800.93M	CHF 285,666.20M